Rapid Score Calculator

This tool combines five variables that are each independently associated with functional outcome after acute ischemic stroke and converts them into a 0 to 14 point prognostic index. Age contributes up to 3 points, with thresholds at 60, 70, and 80 years, because cerebral reserve and rehabilitation potential decline steeply in the eighth and ninth decades. Baseline NIHSS contributes up to 4 points at cut-offs of 5, 10, 15, and 20, and is the single strongest predictor: an NIHSS above 20 marks severe deficit and usually large-vessel occlusion. Admission glucose adds up to 2 points above 140 and 200 mg/dL, since hyperglycemia is linked to larger final infarct volume, poorer reperfusion, and higher symptomatic hemorrhage rates. Systolic blood pressure adds up to 2 points above 160 and 180 mmHg, and onset-to-treatment time up to 3 points beyond 90, 180, and 270 minutes, reflecting the roughly 1.9 million neurons lost per minute of untreated large-vessel ischemia. The outcome being predicted is functional independence at 90 days, conventionally a modified Rankin Scale score of 0 to 2. Totals of 0 to 3 correspond to a good prognosis, 4 to 6 moderate, 7 to 9 poor, and 10 or above very poor. Two caveats are important. First, this is a composite of published predictors rather than a single externally validated published instrument, so the probability bands should be read as approximate ranges, not calibrated risks. Second, a prognostic score must never be used to withhold reperfusion therapy: thrombolysis and thrombectomy eligibility are decided by time window, imaging, and contraindications, and self-fulfilling prophecy from pessimistic early prognostication is a documented hazard in stroke care.

Each input has its own documented lineage. The National Institutes of Health Stroke Scale was developed by Thomas Brott, Harold Adams, and colleagues at the University of Cincinnati and published in Stroke in 1989 as a reproducible 15-item bedside measure for use in acute stroke trials. The outcome measure traces to Dr John Rankin in Glasgow, who published a handicap scale in the Scottish Medical Journal in 1957; it was restructured and given formal interobserver reliability testing by Jan van Swieten and colleagues in Rotterdam in 1988, producing the modified Rankin Scale now used as the primary endpoint in most stroke trials. The time variable entered practice with the NINDS recombinant tissue plasminogen activator trial published in the New England Journal of Medicine in 1995, which established benefit for treatment within three hours, and was extended to four and a half hours by ECASS III in 2008. Pooled analyses by the Stroke Thrombolysis Trialists group later quantified how sharply the odds of a favorable outcome fall with each hour of delay, which is the basis for the escalating time points here. Admission hyperglycemia and elevated blood pressure were identified as independent outcome predictors through large observational registries in the 1990s and 2000s, including work from the Copenhagen Stroke Study and the Get With The Guidelines Stroke registry. Composite indices assembling these same variables, such as the DRAGON, iScore, and ASTRAL scores developed in Helsinki, Toronto, and Lausanne respectively between 2010 and 2013, follow the same design philosophy.